Identification of Hot Spots in the Variola Virus Complement Inhibitor (SPICE) for Human Complement Regulation
Open Access
- 1 April 2008
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (7) , 3283-3294
- https://doi.org/10.1128/jvi.01935-07
Abstract
Variola virus, the causative agent of smallpox, encodes a soluble complement regulator named SPICE. Previously, SPICE has been shown to be much more potent in inactivating human complement than the vaccinia virus complement control protein (VCP), although they differ only in 11 amino acid residues. In the present study, we have expressed SPICE, VCP, and mutants of VCP by substituting each or more of the 11 non-variant VCP residues with the corresponding residue of SPICE to identify hot spots that impart functional advantage to SPICE over VCP. Our data indicate that (i) SPICE is ∼90-fold more potent than VCP in inactivating human C3b, and the residues Y98, Y103, K108 and K120 are predominantly responsible for its enhanced activity; (ii) SPICE is 5.4-fold more potent in inactivating human C4b, and residues Y98, Y103, K108, K120 and L193 mainly dictate this increase; (iii) the classical pathway decay-accelerating activity of activity is only twofold higher than that of VCP, and the 11 mutations in SPICE do not significantly affect this activity; (iv) SPICE possesses significantly greater binding ability to human C3b compared to VCP, although its binding to human C4b is lower than that of VCP; (v) residue N144 is largely responsible for the increased binding of SPICE to human C3b; and (vi) the human specificity of SPICE is dictated primarily by residues Y98, Y103, K108, and K120 since these are enough to formulate VCP as potent as SPICE. Together, these results suggest that principally 4 of the 11 residues that differ between SPICE and VCP partake in its enhanced function against human complement.Keywords
This publication has 56 references indexed in Scilit:
- Natural Antibody and Complement Mediate Neutralization of Influenza Virus in the Absence of Prior ImmunityJournal of Virology, 2007
- Identification of Functional Domains in Kaposica, the Complement Control Protein Homolog of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8)Journal of Virology, 2005
- The Kaposi's Sarcoma-associated Herpesvirus Complement Control Protein Mimics Human Molecular Mechanisms for Inhibition of the Complement SystemJournal of Biological Chemistry, 2004
- SWISS-MODEL: an automated protein homology-modeling serverNucleic Acids Research, 2003
- Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control ProteinsJournal of Virology, 2003
- RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate ProteoglycansCell, 2001
- Independently Melting Modules and Highly Structured Intermodular Junctions within Complement Receptor Type 1Biochemistry, 1999
- Interaction of vaccinia virus complement control protein with human complement proteins: Factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathwayMolecular Immunology, 1998
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Analysis of the nucleotide sequence of 53 kbp from the right terminus of the genome of variola major virus strain India-1967Virus Research, 1994